{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:53:28Z","timestamp":1792788808664,"version":"4.5.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"crossref","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"crossref"}]},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"},{"name":"DICE Therapeutics, a wholly owned subsidiary of Eli Lilly and Company"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Efficacious and well-tolerated systemic, oral treatments for psoriasis are needed. We report preclinical and phase 1c (NCT06808815) results for DC-806, a small molecule interleukin (IL)-17 inhibitor, for the treatment of mild-to-moderate psoriasis. Preclinical results demonstrated DC-806 targets IL-17AA and IL-17AF with secukinumab-like therapeutic efficacy. In the phase 1c trial, 32 patients consented to receive twice daily (BID) doses of placebo or DC-806 (200 mg or 800 mg) for 28 days. No serious adverse events (SAEs) or discontinuations due to treatment-related adverse events (TRAEs) occurred. In an exploratory analysis, adjusted mean percentage reductions from baseline in psoriasis area and severity indices (PASI) at Day 29 were 43.7%, 15.1%, and 13.3% for 800 mg BID, 200 mg BID, and placebo arms, respectively (800 mg BID vs placebo,\n                    <jats:italic>P<\/jats:italic>\n                    value\u2009=\u20090.0008). DC-806 was found to be well tolerated with an acceptable safety profile and preliminary signals of clinical efficacy in mild-to-moderate psoriasis. EudraCT Identifier: 2021-002888-21.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0341049","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:35:07Z","timestamp":1769193307000},"page":"e0341049","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis"],"prefix":"10.1371","volume":"21","author":[{"given":"Richard B.","family":"Warren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish J. A.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4787-742X","authenticated-orcid":true,"given":"Meina T.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Enejosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chieh","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasish","family":"Raha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6180-5505","authenticated-orcid":true,"given":"Hashini M.","family":"Batugedara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Skinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Kobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-3097","authenticated-orcid":true,"given":"Nico","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fatheree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy T.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"3","key":"pone.0341049.ref001","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"A Raharja","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"pone.0341049.ref002","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"JE Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"pone.0341049.ref003","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"FO Nestle","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0341049.ref004","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"JE Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"pone.0341049.ref005","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/jid.2012.163","article-title":"Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial","volume":"132","author":"KA Papp","year":"2012","journal-title":"J Invest Dermatol"},{"key":"pone.0341049.ref006","author":"Bausch Health Americas, Inc.","year":"2023"},{"issue":"18","key":"pone.0341049.ref007","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1074\/jbc.M700499200","article-title":"Identification of an interleukin 17F\/17A heterodimer in activated human CD4+ T cells","volume":"282","author":"JF Wright","year":"2007","journal-title":"J Biol Chem"},{"issue":"4","key":"pone.0341049.ref008","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"MJ McGeachy","year":"2019","journal-title":"Immunity"},{"key":"pone.0341049.ref009","author":"Novartis Pharma Corp.","year":"2016"},{"key":"pone.0341049.ref010","author":"Eli Lilly & Co.","year":"2021"},{"key":"pone.0341049.ref011","author":"UCB Pharma","year":"2023"},{"key":"pone.0341049.ref012","author":"Amgen Inc.","year":"2017"},{"issue":"1","key":"pone.0341049.ref013","doi-asserted-by":"crossref","first-page":"2177095","DOI":"10.1080\/09546634.2023.2177095","article-title":"Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis","volume":"34","author":"JJ Wu","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"pone.0341049.ref014","author":"Bristol-Myers S","year":"2022"},{"key":"pone.0341049.ref015","author":"West-Ward Pharmaceuticals Corp","year":"2020"},{"key":"pone.0341049.ref016","author":"Amgen Inc","year":"2021"},{"key":"pone.0341049.ref017","author":"Novartis","year":"2009"},{"key":"pone.0341049.ref018","doi-asserted-by":"crossref","first-page":"586827","DOI":"10.3389\/fphar.2021.586827","article-title":"Model-based meta-analysis in psoriasis: a quantitative comparison of biologics and small targeted molecules","volume":"12","author":"H He","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"pone.0341049.ref019","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"E Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0341049.ref020","author":"Eli Lilly and Company","year":"2025"},{"issue":"4","key":"pone.0341049.ref021","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"S Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0341049.ref022","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1084\/jem.146.3.857","article-title":"Autoimmunity to type II collagen an experimental model of arthritis","volume":"146","author":"DE Trentham","year":"1977","journal-title":"J Exp Med"},{"issue":"3","key":"pone.0341049.ref023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrd.2017.44","article-title":"New plaque psoriasis approval carries suicide warning","volume":"16","author":"A Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"pone.0341049.ref024","author":"R&D Systems, Inc","year":"2017"},{"issue":"22","key":"pone.0341049.ref025","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.4155\/bio-2016-0207","article-title":"Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis","volume":"8","author":"C Schofield","year":"2016","journal-title":"Bioanalysis"},{"issue":"3","key":"pone.0341049.ref026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"F Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"pone.0341049.ref027","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1208\/s12248-017-0094-4","article-title":"Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin","volume":"19","author":"C Soderstrom","year":"2017","journal-title":"AAPS J"},{"issue":"7","key":"pone.0341049.ref028","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/ced.13561","article-title":"Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis","volume":"43","author":"L Fitz","year":"2018","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"pone.0341049.ref029","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s13555-017-0205-2","article-title":"Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis","volume":"7","author":"M Alcusky","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"pone.0341049.ref030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.36469\/9817","article-title":"Relative importance of mode of administration in treatment preferences among plaque psoriasis patients in the United States","volume":"4","author":"SR Feldman","year":"2016","journal-title":"J Health Econ Outcomes Res"},{"key":"pone.0341049.ref031","doi-asserted-by":"crossref","first-page":"128229","DOI":"10.1016\/j.bmcl.2021.128229","article-title":"Small molecule approaches to treat autoimmune and inflammatory diseases (Part III): Targeting cytokines and cytokine receptor complexes","volume":"48","author":"J Zheng","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"pone.0341049.ref032","doi-asserted-by":"crossref","first-page":"30859","DOI":"10.1038\/srep30859","article-title":"Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists","volume":"6","author":"S Liu","year":"2016","journal-title":"Sci Rep"},{"issue":"11","key":"pone.0341049.ref033","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/13543776.2022.2143264","article-title":"Small molecule modulators of IL-17A\/IL-17RA: a patent review (2013-2021)","volume":"32","author":"B Zhang","year":"2022","journal-title":"Expert Opin Ther Pat"},{"key":"pone.0341049.ref034","author":"Eli Lilly and Company"},{"key":"pone.0341049.ref035","author":"P Leo","year":"2023"},{"issue":"3","key":"pone.0341049.ref036","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1124\/jpet.118.255562","article-title":"Exposure-effect relationships in established rat adjuvant-induced and collagen-induced arthritis: a translational pharmacokinetic-pharmacodynamic analysis","volume":"369","author":"H Wong","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"pone.0341049.ref037","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"S Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0341049.ref038","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"JG Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0341049.ref039","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","author":"DD Patel","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0341049.ref040","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1038\/s41598-019-41609-z","article-title":"Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay","volume":"9","author":"RJ Konrad","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0341049.ref041","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/ijms24021276","article-title":"Interleukin-19 levels are increased in palmoplantar pustulosis and reduced following apremilast treatment","volume":"24","author":"K Wolk","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"pone.0341049.ref042","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1189\/jlb.3HI1215-542R","article-title":"Human mast cells capture, store, and release bioactive, exogenous IL-17A","volume":"100","author":"T Noordenbos","year":"2016","journal-title":"J Leukoc Biol"},{"key":"pone.0341049.ref043","author":"US Center for Drug Evaluation and Research","year":"2015"},{"issue":"11","key":"pone.0341049.ref044","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/jid.2014.308","article-title":"IL-19 is a component of the pathogenetic IL-23\/IL-17 cascade in psoriasis","volume":"134","author":"E Witte","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"4","key":"pone.0341049.ref045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/009286150804200402","article-title":"Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials","volume":"42","author":"CH Mallinckrodt","year":"2008","journal-title":"Drug Information J"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:35:13Z","timestamp":1769193313000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341049"}},"subtitle":[],"editor":[{"given":"Emanuele","family":"Scala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341049","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}